OrBec Future In Doubt: Cmte. Calls For Further Study, But Firm Is Out Of Funds
Executive Summary
With FDA's Oncologic Drugs Advisory Committee one set of concluding that another clinical trial is necessary to prove a benefit of DOR BioPharma's orBec, the graft-versus-host disease drug may have reached the end of the road as the company says it does not have the funding for an additional trial